{"createdAt":"8/2/2020, 2:34:47 PM","timestamp":1596393287071,"Company ID number":"625","DMX_ISSUER_NAME":"HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.","DMX_ISSUER_ID":"IID000000002126627","Country of Classification":"CHINA","name":"Hubei Jumpcan Pharmaceutical Co Ltd ","code":"600566","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"湖北济川药业股份有限公司_曹龙祥","group":"board","name":"曹龙祥","title":"董事长,董事","isMale":true,"age":"63","degree":"硕士","salary":"228.0万","stockAmount":"4684万","description":"曹龙祥先生,1957年9月出生,中国国籍,无境外永久居留权,EMBA,高级经济师,江苏省第十二届人大代表。曾任江苏泰兴农村商业银行股份有限公司董事,湖北济川药业股份有限公司总经理、济川药业集团有限公司董事长兼总经理、济川药业集团江苏银杏产业研究院有限公司总经理、江苏蒲地蓝日化有限公司总经理、济川药业集团江苏口腔健康研究院有限公司总经理、济川药业集团药品销售有限公司总经理、江苏济康医药包装有限公司总经理。现任湖北济川药业股份有限公司董事长,江苏济川控股集团有限公司董事长、江苏济源医药有限公司执行董事、济川药业集团江苏银杏产业研究院有限公司执行董事、江苏蒲地蓝日化有限公司执行董事、济川药业集团江苏口腔健康研究院有限公司研究院执行董事、泰州市为你想大药房连锁有限公司执行董事、济川药业集团药品销售有限公司执行董事、江苏济康医药包装有限公司执行董事、泰兴市人医新特药房有限公司执行董事,江苏宝塔水泥有限公司监事。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_黄曲荣","group":"board","name":"黄曲荣","title":"副董事长,董事","isMale":true,"age":"58","degree":"大专","salary":"151.2万","stockAmount":"-","description":"黄曲荣先生,1962年1月出生,中国国籍,无境外永久居留权,大专学历,高级经济师。曾任江苏济川制药有限公司常务副总经理、湖北济川药业股份有限公司常务副总经理、济川药业集团有限公司常务副总经理,现任湖北济川药业股份有限公司副董事长、济川药业集团有限公司副董事长,江苏济川控股集团有限公司董事。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_曹飞","group":"board","name":"曹飞","title":"副董事长,董事","isMale":true,"age":"37","degree":"硕士","salary":"--","stockAmount":"-","description":"曹飞先生,1983年7月出生,中国国籍,无境外永久居留权,硕士。曾就职于上海复星医药(集团)股份有限公司,曾任江苏济川控股集团有限公司总经理、江苏济源医药有限公司董事、江苏天济药业有限公司执行董事、济川药业集团泰兴市济仁中药饮片有限公司执行董事、江苏济川康煦源保健品有限公司执行董事,现任湖北济川药业股份有限公司副董事长兼总经理,江苏济川控股集团有限公司董事,济川药业集团有限公司董事长,济川(上海)医学科技有限公司执行董事、上海济嘉投资有限公司执行董事、宁波济嘉投资有限公司执行董事、陕西东科制药有限责任公司董事长。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_刘俊","group":"board","name":"刘俊","title":"董事","isMale":true,"age":"45","degree":"博士","salary":"136.3万","stockAmount":"-","description":"刘俊先生,1975年11月出生,中国国籍,无境外永久居留权,博士。曾任江苏省人民政府研究室综合处主任科员、副调研员、经济发展研究中心副主任、泰兴市人民政府副市长(挂职)、江苏省人民政府研究室社会处副处长、济川药业集团有限公司副总经理,现任湖北济川药业股份有限公司董事、副总经理,济川药业集团有限公司总经理,中共济川药业集团有限公司党委副书记。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_姚宏","group":"board","name":"姚宏","title":"独立董事","isMale":true,"age":"46","degree":"博士","salary":"0.00","stockAmount":"-","description":"姚宏先生,1974年8月出生,中国国籍,无境外永久居留权,博士,高级经济师。曾任上海市财政局办公室副主任。现任高林资本管理有限公司合伙人、北京宅急送快运股份有限公司监事会主席、松树铭志(上海)股权投资管理有限公司董事长。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_卢超军","group":"board","name":"卢超军","title":"独立董事","isMale":true,"age":"50","degree":"硕士","salary":"0.00","stockAmount":"-","description":"卢超军先生,1970年10月出生,中国国籍,无境外永久居留权,硕士。曾任职于上海何正大律师事务所,曾任广东东方兄弟投资股份有限公司董事、万鸿集团股份有限公司独立董事,现任职于上海嘉坦律师事务所。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_朱四一","group":"board","name":"朱四一","title":"独立董事","isMale":true,"age":"51","degree":"硕士","salary":"0.00","stockAmount":"-","description":"朱四一先生,1969年6月出生,中国国籍,无境外永久居留权,硕士学历,高级会计师。曾任皖北煤电集团有限责任公司资产财务部主任会计师、副部长,安徽恒源煤电股份有限公司计划财务部副部长、部长。现任安徽恒源煤电股份有限公司董事、财务总监、董事会秘书。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_孙荣","group":"supervisoryCommittee","name":"孙荣","title":"监事会主席","isMale":true,"age":"63","degree":"本科","salary":"62.67万","stockAmount":"-","description":"孙荣先生,1957年6月出生,中国国籍,无境外永久居留权,本科学历,政工师。曾任江苏济川制药有限公司副总经理,现担任公司监事会主席、济川药业集团有限公司监事会主席、济川药业集团江苏口腔健康研究院有限公司监事、济川药业集团江苏银杏产业研究院有限公司监事、江苏蒲地蓝日化有限公司监事、济川药业集团电子商务有限公司监事、江苏蒲地蓝药妆科技有限公司监事、江苏济康医药包装有限公司监事、江苏济川控股集团有限公司监事、西藏济川创业投资管理有限公司监事。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_周新春","group":"supervisoryCommittee","name":"周新春","title":"监事","isMale":true,"age":"51","degree":"大专","salary":"30.68万","stockAmount":"-","description":"周新春,男,1969年1月6日出生,大专学历,中国国籍,无境外居留权,中国共产党党员。1991年8月至1999年5月任泰兴酒精厂办公室主任;1999年6月至2005年5月任上海因特尔电子技术有限公司西南区经理;2005年6月至今,历任济川药业集团有限公司人力资源部经理、薪酬管理部经理、监督管理中心副主任,现任济川药业集团有限公司物资采购中心管理总监。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_石珊","group":"supervisoryCommittee","name":"石珊","title":"职工监事","isMale":false,"age":"30","degree":"硕士","salary":"12.29万","stockAmount":"-","description":"石珊女士,1990年6月出生,中国国籍,无境外永久居留权,硕士。湖北济川药业股份有限公司财务部总帐辅助,现任湖北济川药业股份有限公司资本运营中心办公室主任助理。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_曹飞","group":"manager","name":"曹飞","title":"总经理","isMale":true,"age":"37","degree":"硕士","salary":"--","stockAmount":"-","description":"曹飞先生,1983年7月出生,中国国籍,无境外永久居留权,硕士。曾就职于上海复星医药(集团)股份有限公司,曾任江苏济川控股集团有限公司总经理、江苏济源医药有限公司董事、江苏天济药业有限公司执行董事、济川药业集团泰兴市济仁中药饮片有限公司执行董事、江苏济川康煦源保健品有限公司执行董事,现任湖北济川药业股份有限公司副董事长兼总经理,江苏济川控股集团有限公司董事,济川药业集团有限公司董事长,济川(上海)医学科技有限公司执行董事、上海济嘉投资有限公司执行董事、宁波济嘉投资有限公司执行董事、陕西东科制药有限责任公司董事长。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_曹伟","group":"manager","name":"曹伟","title":"董事会秘书","isMale":true,"age":"34","degree":"硕士","salary":"87.56万","stockAmount":"-","description":"曹伟先生,男,1986年9月生,硕士研究生学历,中国国籍,无境外永久居留权,中国共产党党员。曾任国金证券股份有限公司投资银行部项目经理,百川能源股份有限公司董事。现任湖北济川药业股份有限公司全资子公司上海济嘉投资有限公司经理、宁波济嘉投资有限公司经理、陕西东科制药有限责任公司董事、上海贞信企业管理咨询有限公司执行董事。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_刘俊","group":"manager","name":"刘俊","title":"副总经理","isMale":true,"age":"45","degree":"博士","salary":"136.3万","stockAmount":"-","description":"刘俊先生,1975年11月出生,中国国籍,无境外永久居留权,博士。曾任江苏省人民政府研究室综合处主任科员、副调研员、经济发展研究中心副主任、泰兴市人民政府副市长(挂职)、江苏省人民政府研究室社会处副处长、济川药业集团有限公司副总经理,现任湖北济川药业股份有限公司董事、副总经理,济川药业集团有限公司总经理,中共济川药业集团有限公司党委副书记。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_张建民","group":"manager","name":"张建民","title":"副总经理","isMale":true,"age":"50","degree":"本科","salary":"312.3万","stockAmount":"-","description":"张建民先生,1970年7月出生,中国国籍,无境外永久居留权,本科学历。曾任江苏济川制药有限公司副总经理,现任湖北济川药业股份有限公司副总经理、济川药业集团有限公司副总经理。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_周其华","group":"manager","name":"周其华","title":"副总经理","isMale":true,"age":"55","degree":"本科","salary":"177.1万","stockAmount":"-","description":"周其华先生,1965年4月出生,中国国籍,无境外永久居留权,本科学历。曾任江苏济川制药有限公司副总经理,现任湖北济川药业股份有限公司副总经理、济川药业集团有限公司副总经理。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_严宏泉","group":"manager","name":"严宏泉","title":"副总经理","isMale":true,"age":"52","degree":"大专","salary":"73.01万","stockAmount":"-","description":"严宏泉先生,1968年7月出生,中国国籍,无境外永久居留权,大专学历,会计师。曾任江苏济川制药有限公司副总经理,现任湖北济川药业股份有限公司副总经理、济川药业集团有限公司副总经理。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_吴宏亮","group":"manager","name":"吴宏亮","title":"财务总监","isMale":true,"age":"42","degree":"大专","salary":"56.85万","stockAmount":"-","description":"吴宏亮先生,1978年1月出生,中国国籍,无境外永久居留权,大专学历,中级会计师。曾任山西振东制药股份有限公司财务经理、财务总监、财务负责人,邯郸摩罗丹药业股份有限公司财务总监,江苏济川制药有限公司财务总监,公司董事会秘书。现任湖北济川药业股份有限公司财务总监,济川药业集团有限公司财务总监。","lastUpdated":"2020-03-03"},{"id":"湖北济川药业股份有限公司_史文正","group":"manager","name":"史文正","title":"人力资源总监","isMale":true,"age":"42","degree":"硕士","salary":"61.94万","stockAmount":"-","description":"史文正先生,1978年10月出生,中国国籍,无境外永久居留权,硕士。曾任青岛华狮化工有限公司总经理助理、上海联合纵横管理咨询有限公司项目经理、江苏济川制药有限公司人力资源总监、济川药业集团有限公司副总经理,现任湖北济川药业股份有限公司人力资源总监。","lastUpdated":"2020-03-03"}],"companyName":"湖北济川药业股份有限公司","province":"湖北省","englishName":"Hubei Jumpcan Pharmaceutical Co Ltd","industry":"医药生物 — 中药Ⅱ","website":"www.jumpcan.com","mainBusiness":"药品的研发、生产和销售","productsName":["蒲地蓝消炎口服液","雷贝拉唑钠肠溶胶囊","小儿豉翘清热颗粒"],"actualController":"曹龙祥","actualControllerSharePercentage":"50.14%","registeredCapital":"8.15亿元","employeeAmount":"7073","phone":"86-0523-89719161","location":"江苏省泰州市泰兴市大庆西路宝塔湾","chineseDescription":"湖北济川药业股份有限公司主营业务为药品的研发、生产和销售，主要产品包括蒲地蓝消炎口服液、小儿豉翘清热颗粒、健胃消食口服液等。在企业品牌方面，报告期内，济川有限入选江苏省工业与信息化厅评选的“2018年度江苏省自主工业品牌五十强”；荣获中国消费经济高层论坛及消费日报社联合评选的“3.15健康中国医药行业十大影响力品牌”。\n　　蒲地蓝消炎口服液和小儿豉翘清热颗粒分别荣获《中国药店》杂志主办的中国药店高峰论坛颁发的清热解毒类和儿童用药类“2018-2019年度中国药店店员推荐率最高品牌”；小儿豉翘清热颗粒荣获中国中药协会主办的2019中国中药品牌建设大会颁发的“2019年度临床价值中成药品牌”；济诺...查看全部▼湖北济川药业股份有限公司主营业务为药品的研发、生产和销售，主要产品包括蒲地蓝消炎口服液、小儿豉翘清热颗粒、健胃消食口服液等。在企业品牌方面，报告期内，济川有限入选江苏省工业与信息化厅评选的“2018年度江苏省自主工业品牌五十强”；荣获中国消费经济高层论坛及消费日报社联合评选的“3.15健康中国医药行业十大影响力品牌”。\n　　蒲地蓝消炎口服液和小儿豉翘清热颗粒分别荣获《中国药店》杂志主办的中国药店高峰论坛颁发的清热解毒类和儿童用药类“2018-2019年度中国药店店员推荐率最高品牌”；小儿豉翘清热颗粒荣获中国中药协会主办的2019中国中药品牌建设大会颁发的“2019年度临床价值中成药品牌”；济诺（雷贝拉唑钠肠溶胶囊）入选米内网主办的全国医药经济信息发布会公布的“2019中国医药品牌榜”。收起▲","foundedDate":"1997-01-22","goPublicDate":"2001-08-22","companyHistory":"湖北济川药业股份有限公司（以下简称“公司”或“本公司”）前身为湖北洪城通用机械股份有限公司，系于1996年经湖北省体改委鄂体改（1996）373号文件批准，由荆州市国有资产管理局（原荆沙市国有资产管理局）、湖北沙市阀门总厂、沙市精密钢管总厂、湖北大日化工股份有限公司（原荆沙市江陵化肥厂）、湖北永盛石棉橡胶有限公司（原荆沙市石棉橡胶厂）、荆州市荆沙棉纺织有限公司（原荆沙市荆沙棉纺织厂）等六家单位共同发起设立的股份有限公司。公司于1997年1月22日取得湖北省工商行政管理局颁布的企业法人营业执照，注册号：420000000034415。\n　　2001年7月，经中国证券监督管理委员会证监发行字（2001）48号文核准，公司向社会发行新股4,000万股，每股价格为7.80元，发行后总股本为106,308,000股。经2010年4月27日召开的2009年年度股东大会审议通过，公司以资本公积向全体股东每10股转增3股。转增股本总数31,892,400股，转增股本后公司总股本为138,200,400股。\n　　2013年12月，根据公司2013年第一次临时股东大会决议，并经中国证券监督管理委员会核发的《关于核准湖北洪城通用机械股份有限公司重大资产重组及向江苏济川控股集团有限公司等发行股份购买资产并募集配套资金的批复》（证监许可[2013]1604号）核准，公司通过向江苏济川控股集团有限公司、曹龙祥、周国娣、西藏华金济天投资有限公司和西藏恒川投资管理中心（有限合伙）（上述五方以下简称“重组方”）发行股份购买资产，申请增加注册资本人民币61,082.4301万元，变更后的注册资本为人民币74,902.4701万元。本次变更已经立信会计师事务所（特殊普通合伙）信会师报字（2013）第114211号验资报告验证，本次注册资本变更已在荆州市工商行政管理局办理了工商变更登记。\n　　2014年1月，公司向社会非公开发行人民币普通股（A股）3,243万股，申请增加注册资本人民币3,243万元，变更后的注册资本为人民币78,145.4701万元。本次变更已经立信会计师事务所（特殊普通合伙）信会师报字（2014）第110050号验资报告验证，本次注册资本变更已在荆州市工商行政管理局办理了工商变更登记。\n　　2016年6月，公司向社会非公开发行人民币普通股（A股）2,816.9298万股，申请增加注册资本人民币2,816.9298万元，变更后的注册资本为人民币80,962.3999万元。本次变更已经立信会计师事务所（特殊普通合伙）信会师报字（2016）第114698号验资报告验证，本次注册资本变更已在荆州市工商行政管理局办理了工商变更登记。\n　　截止2017年06月30日，本公司累计发行股本总数80,962.3999万股，注册资本为80,962.3999万元。注册地：湖北省荆州市沙市区园林路时尚豪庭602室；总部地址：江苏省泰兴市大庆西路宝塔湾；法定代表人：曹龙祥。\n　　2017年11月，根据公司2017年第二次临时股东大会决议，并经中国证券监督管理委员会核发的《关于核准湖北济川药业股份有限公司公开发行可转换公司债券的批复》（证监许可［2017］1755号）核准，公司向社会公开发行面值总额为人民币84,316万元可转换公司债券，每张面值人民币100元，共843.16万张，期限5年。\n　　截止2019年12月31日，本公司累计发行股本总数81,492.2174万股。收起▲","shareholders":[{"organizationId":"T000126987","holderName":"江苏济川控股集团有限公司","totalShare":"4.17亿","sharePercentage":"51.14%"},{"organizationId":"T000700233","holderName":"西藏济川创业投资管理有限公司","totalShare":"1.00亿","sharePercentage":"12.27%"},{"organizationId":"","holderName":"曹龙祥","totalShare":"4683.85万","sharePercentage":"5.75%"},{"organizationId":"00089666","holderName":"荆州市古城国有投资有限责任公司","totalShare":"1112.61万","sharePercentage":"1.37%"},{"organizationId":"","holderName":"银河资本-浙商银行-银河资本-鑫鑫一号资产管理计划","totalShare":"947.22万","sharePercentage":"1.16%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"933.96万","sharePercentage":"1.15%"},{"organizationId":"","holderName":"中国工商银行股份有限公司-东方红产业升级灵活配置混合型证券投资基金","totalShare":"846.65万","sharePercentage":"1.04%"},{"organizationId":"","holderName":"国泰君安证券资管-光大银行-国泰君安君得明混合型集合资产管理计划","totalShare":"640.00万","sharePercentage":"0.79%"},{"organizationId":"","holderName":"全国社保基金一一六组合","totalShare":"532.00万","sharePercentage":"0.65%"},{"organizationId":"03131099","holderName":"国泰君安证券股份有限公司","totalShare":"506.53万","sharePercentage":"0.62%"}],"englishDescription":"HUBEI JUMPCAN PHARMACEUTICAL CO., LTD., formerly Hubei Hongcheng General Machinery Co., Ltd., is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The Company mainly distributes its products within domestic markets. ","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"13.10","Price to sales (ttm)":"3.00","Price to book (mrq)":"3.14","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"11.46","Lt debt to equity (mrq)":"8.87","Return on investment (ttm)":"22.60","Return on equity (ttm)":"17.51","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"7,850.48","Cash payments":"(884.66)","Cash taxes paid":"(1,089.62)","Changes in working capital":"(3,728.53)","Cash from operating activities":"2,147.68","Capital expenditures":"(546.44)","Other investing cash flow items, total":"101.98","Cash from investing activities":"(444.46)","Total cash dividends paid":"(1,005.31)","Issuance (retirement) of debt, net":"(0.00)","Cash from financing activities":"(1,005.31)","Net change in cash":"697.91","Financing cash flow items":"(94.70)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"25.32","52 Week High":"31.30","52 Week Low":"19.60","Pricing date":"","10 Day Average Trading Volume":"10.55","Market Capitalization":"20,633.92","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"224.45","Beta":"0.65","1 Day Price Change":"0.76","13 Week Price Return (Daily)":"22.20","26 Week Price Return (Daily)":"-2.84","5 Day Price Return (Daily)":"2.84","52 Week Price Return (Daily)":"-12.93","Year To Date Price Return (Daily)":"4.71","Month to Date Price Return (Daily)":"-0.55","Price Relative to S&P500 (4 Week)":"-7.13","Price Relative to S&P500 (13 Week)":"5.59","Price Relative to S&P500 (26 Week)":"-12.63","Price Relative to S&P500 (52 Week)":"-23.48","Price Relative to S&P500 (YTD)":"-3.51"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.99","EPS excl. Extra Items (TTM)":"1.93","EPS Normalized (Annual)":"1.99","Revenue per Share (Annual)":"8.52","Revenue per Share (TTM)":"8.42","Book Value (Per Share Annual)":"7.49","Book Value (Per Share Quarterly)":"8.06","Tangible Book Value (Per Share Annual)":"6.87","Tangible Book Value (Per Share Quarterly)":"7.45","Cash Per Share (Per Share Annual)":"3.04","Cash Per Share (Per Share Quarterly)":"3.76","Cash Flow (Per Share Annual)":"2.28","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"1.23","Dividends (Per Share TTM)":"1.23","EBITD (Per Share TTM)":"2.15","EPS Basic excl. Extra Items (Annual)":"1.99","EPS Basic excl. Extra Items (TTM)":"1.94","EPS incl. Extra Items (Annual)":"1.99","EPS incl. Extra Items (TTM)":"1.93","Free Cash Flow (Per Share TTM)":"0.88","Dividend (Per Share 5Y)":"0.98"},"Valuation":{"P/E excl. Extra Items (Annual)":"12.71","P/E excl. Extra Items (TTM)":"13.10","P/E Normalized (Annual)":"12.70","Price to sales (Annual)":"2.97","Price to sales (TTM)":"3.00","Price to Tangible Book (Annual)":"3.68","Price to Tangible Book (Quarterly)":"3.40","Price to Free Cash Flow (Per Share Annual)":"34.62","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"28.69","Price to Book (Annual)":"3.38","Price to Book (Quarterly)":"3.14","P/E Basic excl. Extra Items (TTM)":"11.33","P/E excl. Extra Items High (TTM)":"31.84","P/E excl. Extra Items Low (TTM)":"11.34","P/E incl. Extra Items (TTM)":"13.10","Net Debt (Interim)":"-2,309.98","Net Debt (Annual)":"-1,748.27","Dividend Yield (5Y)":"3.16","Dividend Yield":"4.86","Current Dividend Yield (TTM)":"4.86"},"Financial Strength":{"Free Cash Flow (Annual)":"595.93","Current Ratio (Annual)":"2.67","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"9.44","Payout Ratio (Annual)":"61.76","Quick Ratio (Annual)":"2.49","Total Debt/Total Equity (Annual)":"11.90","Current EV/Free Cash Flow (Annual)":"62.46","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"2.63","Long Term Debt/Equity (Quarterly)":"8.87","Quick Ratio (Quarterly)":"2.49","Total Debt/Total Equity (Quarterly)":"11.46","Free Cash Flow (TTM)":"719.21","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"63.56"},"Margins":{"Gross Margin (Annual)":"84.00","Gross Margin (TTM)":"81.75","Net Profit Margin % (Annual)":"23.39","Net Profit Margin (TTM)":"22.96","Operating Margin (Annual)":"26.77","Operating Margin (TTM)":"26.65","Pretax Margin (TTM)":"26.77","Pretax Margin (Annual)":"27.28","Operating Margin (5Y)":"24.58","Pretax Margin (5Y)":"25.47","Free Operating Cash Flow/Revenue (5Y)":"2.32","Free Operating Cash Flow/Revenue (TTM)":"10.47","Gross Margin (5Y)":"84.55","Net Profit Margin (5Y)":"21.79"},"Management Effectiveness":{"Return on Assets (Annual)":"19.72","Return on Equity (TTM)":"17.51","Return on Average Equity (Annual)":"28.07","Return on Average equity (TTM)":"25.15","Return on Investment (Annual)":"25.06","Return on Investment (TTM)":"22.60","Return on Average Assets (5Y)":"21.18","Return on Average Equity (5Y)":"30.20","Return on Investment (5Y)":"27.59","Asset Turnover (Annual)":"0.84","Asset Turnover (TTM)":"0.76","Inventory Turnover (Annual)":"3.38","Inventory Turnover (TTM)":"4.20","Net Income/Employee (Annual)":"228,298.50","Net Income/Employee (TTM)":"222,956.40","Receivables Turnover (Annual)":"3.64","Receivables Turnover (TTM)":"3.20","Revenue/Employee (Annual)":"976,226.40","Revenue/Employee (TTM)":"971,057.40"},"Growth":{"Revenue Growth (Quarterly YoY)":"-3.45","Revenue Growth Rate (5Y)":"18.37","EPS Growth (Quarterly YoY)":"-9.02","EPS Growth (TTM YoY)":"-9.09","EPS Growth Rate (5Y)":"24.54","Dividend Growth Rate (3Y)":"18.99","Revenue Growth (TTM YoY)":"-4.07","Revenue Growth (Per Share 5Y)":"17.38","Revenue Growth Rate (3Y)":"14.05","EPS Growth Rate (3Y)":"19.40","Book Value Growth Rate (Per Share 5Y)":"20.61","Tangible Book Value Total Equity CAGR (5Y)":"21.08","Capital Spending growth rate 5 year":"12.63","EBITDA CAGR (5Y)":"26.47","EBITDA Interim CAGR (5Y)":"24.10","Free Operating Cash Flow CAGR (5Y)":"16.96","Total Debt CAGR (5Y)":"17.57","Net Profit Margin Growth Rate (5Y)":"6.10"},"Income Statement":{"Revenue (Annual)":"6,939.99","Revenue (TTM)":"6,868.29","EBITD (Annual)":"2,045.82","EBITD (TTM)":"1,753.78","Earnings Before Taxes (Annual)":"1,893.15","Earnings Before Taxes (TTM)":"1,838.93","Net Income to Common (Annual)":"1,622.97","Net Income to Common (TTM)":"1,576.97","Earnings Before Taxes Normalized (Annual)":"1,894.84","Net Income Available to Common Normalized (Annual)":"1,624.43","Diluted Normalized EPS excl. Extra Items (TTM)":"1.91"}}}